Lucero Olivia M, Fitzmaurice Sarah, Thompson Curtis, Leitenberge Justin
Departments of Dermatology, Oregon Health & Sciences University, Portland, Oregon.
Dermatol Online J. 2018 Feb 15;24(2):13030/qt92k2f96t.
Vismodegib is a small molecule inhibitor of the Hedgehog signaling pathway that has shown efficacy in the control of locally advanced or metastatic basal cell carcinoma, although proof of its effectiveness in the elimination of aggressive tumors is lacking. We report a case and provide complete histological evidence of a 69-year-old gentleman who presented with a recurrent, infiltrative, and sclerosing (morpheiform) basal cell carcinoma on his left upper lip that was entirely eradicated with a three-month course of vismodegib 150 mg daily. Complete histologic clearance of a tumor in a recurrent, infiltrative, and sclerosing basal cell carcinoma with vismodegib is uncommon.
维莫德吉是一种Hedgehog信号通路的小分子抑制剂,已显示出在控制局部晚期或转移性基底细胞癌方面的疗效,尽管缺乏其在消除侵袭性肿瘤方面有效性的证据。我们报告了一例病例,并提供了完整的组织学证据,该69岁男性患者左上唇出现复发性、浸润性和硬化性(硬斑病样)基底细胞癌,每日服用150mg维莫德吉,疗程三个月后肿瘤完全消除。维莫德吉使复发性、浸润性和硬化性基底细胞癌的肿瘤实现完全组织学清除的情况并不常见。